Abstract Number: PB0757
Meeting: ISTH 2021 Congress
Background: Chemotherapy-induced thrombocytopenia (CIT) is a common complication of cancer therapy and platelet transfusions are the most frequently used treatment option, however, the management strategies of CIT among different specialists vary significantly.
Aims: The aim of our study was to evaluate the management practices of CIT with platelet transfusions by hematologists and oncologists in Armenia.
Methods: A survey was conducted among the physicians of the Hematology Center after Prof. R.H. Yeolyan.
Results: From 38 respondents 15 were adults’ hematologists, 7 oncologists, 16 pediatric hematologists/oncologists. 66% (25) of them had ⩽ 6 years of professional experience, 16% (6) ⩾ 10 years, and 18% (7) ⩾ 20 years.
13.2% (5) of physicians considered thrombocytopenia when platelet count falls below 180×109/L, 42.1% (16) <150×109/L, 15.8% (6) <140×109/L, 21.1% (8) <100×109/L. All 38 physicians were favoring prophylactic transfusions over on-demand transfusions. For 73.3% (11) of adults’ hematologists, 57.1% (4) of adults’ oncologists, and 50% (8) of pediatricians 10×109/L PLT count was threshold for transfusing afebrile (non-APL) patients. 81.3% (13) of adults’ hematologists, 57.1% (4) of adults’ oncologists and 73.3% (11) of pediatricians would transfuse febrile (non-APL) patients when PLT <20×109/L. Afebrile and febrile adults with APL would get transfusions by 75% (12) and 73.3% (11) of hematologists when PLT <20×109/L, respectively. 56.3% (9) of pediatricians would transfuse both afebrile and febrile patients with APL when PLT <50×109/L. 53% (20) mentioned 24/7 access to platelet products.
67% of adults’ hematologists and oncologists mentioned that the cost of platelet products affects their decision on making prophylactic transfusion because patients have to pay out-of-pocket.
Conclusions: Our cohort physicians prefer PLT transfusions for prophylaxis not only on-demand. When it comes to febrile (non-APL) patients the majority of them prioritize 20×109/L over 10×109/L as threshold. Their decision on making a transfusion is mainly affected by financial factors.
To cite this abstract in AMA style:Hambardzumyan L, Movsisyan A, Badikyan M, Martirosyan N, Khachatryan H, Sevoyan A, Grigoryan H, Martirosyan N, Tamamyan G, Danielyan S. Chemotherapy-induced Thrombocytopenia and Platelet Transfusions in Hematology/Oncology Practice [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 2). https://abstracts.isth.org/abstract/chemotherapy-induced-thrombocytopenia-and-platelet-transfusions-in-hematology-oncology-practice/. Accessed May 16, 2022.
« Back to ISTH 2021 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/chemotherapy-induced-thrombocytopenia-and-platelet-transfusions-in-hematology-oncology-practice/